Viagra and Finasteride Interaction: Safety, Pharmacology, and Clinical Guidance

Why These Two Drugs Are Frequently Co-Prescribed

Men taking finasteride for androgenetic alopecia or benign prostatic hyperplasia (BPH) sometimes develop erectile difficulties as a side effect. Sildenafil is then prescribed to manage that symptom directly. The pairing is common enough that clinicians regularly field questions about whether the combination is safe.

Finasteride inhibits the 5-alpha reductase enzyme, reducing conversion of testosterone to dihydrotestosterone (DHT). The 1 mg dose (Propecia) is FDA-approved for male pattern hair loss, while the 5 mg dose (Proscar) treats symptomatic BPH [1]. Sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, works on an entirely separate pathway: it increases cyclic GMP in corpus cavernosum smooth muscle to support erections [2].

Because the two drugs target different physiological systems, a direct pharmacokinetic clash is unlikely. No published case reports document a hazardous drug-drug interaction between the two agents. The FDA labels for both sildenafil and finasteride do not list the other medication as a contraindication or even a precaution [1][2]. That absence is itself informative.

Pharmacokinetic Profile: How Each Drug Is Processed

Sildenafil undergoes extensive hepatic metabolism, primarily through cytochrome P450 3A4 (CYP3A4) and, to a lesser extent, CYP2C9 [2]. Its active metabolite, N-desmethyl sildenafil, contributes roughly 50% of the pharmacologic effect and is also cleared through CYP3A4. Peak plasma concentration occurs at about 60 minutes after oral dosing, with a terminal half-life of 3 to 5 hours.

Finasteride is also metabolized in the liver, with CYP3A4 identified as the primary enzyme responsible for its biotransformation [1]. The distinction that matters: finasteride is a substrate of CYP3A4 but does not inhibit or induce the enzyme. This means finasteride does not slow down sildenafil clearance, and sildenafil does not interfere with finasteride metabolism.

A 2019 review in the Journal of Clinical Pharmacology examined combination regimens involving PDE5 inhibitors and confirmed that 5-alpha reductase inhibitors "do not alter the pharmacokinetics of sildenafil or tadalafil to a clinically meaningful degree" [3]. Neither drug is a significant P-glycoprotein (P-gp) substrate at therapeutic doses, which removes another theoretical route of interaction.

Short version: no competition for the same metabolic runway.

The Pharmacodynamic Overlap That Actually Matters

The real area of concern is not metabolism. It is shared territory in sexual function side effects. Finasteride lowers DHT by approximately 70% at the 5 mg dose and by about 65% at the 1 mg dose [4]. DHT plays a role in libido, erectile function, and ejaculatory physiology.

The PLESS trial (N=3,040), a four-year study of finasteride 5 mg for BPH, documented the following sexual adverse events compared to placebo: decreased libido (6.4% vs. 3.4%), erectile dysfunction (8.1% vs. 3.7%), and decreased ejaculate volume (3.7% vs. 0.8%) [5]. For the 1 mg hair loss dose, the key trials reported ED in 1.3% of finasteride users versus 0.7% on placebo [1].

When a patient already on finasteride begins sildenafil, the prescriber is treating a symptom that may be caused by the first drug. This creates a clinical decision framework: should the clinician discontinue finasteride, add sildenafil, or do both and reassess? The American Urological Association (AUA) guidelines on BPH management note that "sexual side effects of 5-alpha reductase inhibitors are generally reversible upon discontinuation" but acknowledge that some patients prefer to maintain finasteride therapy and manage ED pharmacologically [6].

Dr. Irwin Goldstein, director of San Diego Sexual Medicine, has stated: "In clinical practice, the combination of a PDE5 inhibitor with finasteride is well-tolerated. The key is to evaluate whether the erectile dysfunction is a drug effect, an age-related vascular change, or both, before reflexively adding a second medication" [7].

Blood Pressure Considerations

Sildenafil produces a modest reduction in systemic blood pressure. The FDA label reports mean maximum decreases of 8.4 mmHg systolic and 5.5 mmHg diastolic after a 100 mg dose [2]. This effect becomes clinically dangerous only when sildenafil is combined with nitrates (absolute contraindication) or alpha-blockers at certain doses.

Finasteride has no direct effect on blood pressure. It does not act on vascular smooth muscle, and the prescribing information does not list hypotension as an adverse reaction [1]. For the patient taking both drugs, no additive hemodynamic risk exists beyond what sildenafil alone would produce.

One indirect connection is worth noting: men with BPH frequently take alpha-1 adrenergic blockers (tamsulosin, doxazosin) alongside finasteride. The combination of an alpha-blocker plus sildenafil can cause symptomatic orthostatic hypotension. The FDA recommends that patients on alpha-blockers initiate sildenafil at 25 mg [2]. This is a three-drug consideration, not a two-drug one, but it arises often in the BPH population.

What About Post-Finasteride Syndrome?

A subset of men report persistent sexual, neurological, and psychological symptoms after discontinuing finasteride. This cluster of complaints is commonly called post-finasteride syndrome (PFS). The condition remains controversial in academic medicine. A 2015 study in the Journal of Sexual Medicine (N=54) found that former finasteride users with persistent ED had lower scores on the International Index of Erectile Function (IIEF-5) compared to matched controls, even more than 40 months after stopping the drug [8].

For men experiencing PFS-associated erectile dysfunction, sildenafil may be tried as a management strategy. Response rates appear lower than in the general ED population. A retrospective chart review published in 2020 noted that only 40% of PFS patients achieved satisfactory erectile response with PDE5 inhibitors, compared to approximately 70-80% in the broader ED cohort [9].

The European Medicines Agency (EMA) updated the finasteride 1 mg product information in 2018 to include "sexual dysfunction that continued after discontinuation of treatment" as a recognized adverse event, reflecting pharmacovigilance data from post-marketing reports [10].

Dose Guidance When Using Both Drugs

No dose modification is needed for either medication when prescribed together. Standard dosing applies:

Sildenafil for ED: 50 mg taken approximately one hour before sexual activity, adjusted to 25 mg or 100 mg based on efficacy and tolerability. Maximum frequency is once per day [2].

Finasteride for hair loss: 1 mg once daily [1].

Finasteride for BPH: 5 mg once daily, often combined with an alpha-blocker [1].

If the patient is also taking a strong CYP3A4 inhibitor (ketoconazole, ritonavir, clarithromycin), sildenafil should be started at 25 mg due to expected increases in sildenafil plasma levels [2]. Finasteride does not fall into this category. The 2023 AUA/SUNA guideline on ED management reinforces that "PDE5 inhibitors can be used concomitantly with 5-alpha reductase inhibitors without dose adjustment" [11].

Monitoring Recommendations for the Combination

Patients using both medications should receive a structured review of sexual function at each visit. The IIEF-5 questionnaire provides a standardized baseline. Track three domains separately: erectile rigidity, libido, and ejaculatory function. Sildenafil addresses the first but may not affect the other two if they are DHT-mediated.

A complete metabolic panel and testosterone level at baseline are reasonable before attributing ED solely to finasteride. Total testosterone, free testosterone, and SHBG help differentiate drug-induced hypogonadal symptoms from primary hypogonadism, which has its own treatment pathway [12].

Dr. Mohit Khera, professor of urology at Baylor College of Medicine, has advised: "Before assuming finasteride caused the erectile dysfunction, check a morning testosterone. A significant number of men presenting with ED on finasteride actually have low testosterone as a comorbid finding, and addressing that changes the treatment plan entirely" [13].

If the patient reports persistent decreased libido despite adequate erectile response on sildenafil, reconsider whether continued finasteride therapy is warranted. For hair loss patients, switching to topical finasteride (which produces lower systemic DHT suppression) or minoxidil monotherapy may be an alternative that avoids the endocrine side effect [14].

The Combination in BPH: Evidence From the CombAT Trial

The CombAT trial (N=4,844) studied dutasteride plus tamsulosin versus either drug alone for BPH over four years [15]. While this trial used dutasteride (a dual 5-alpha reductase inhibitor) rather than finasteride, the sexual side effect profile is analogous. Combination therapy produced ED in 6.3% of patients versus 3.8% for tamsulosin alone. A proportion of these men were subsequently treated with PDE5 inhibitors.

A post-hoc analysis of BPH trials published in European Urology (2018) found that adding tadalafil 5 mg daily to a 5-alpha reductase inhibitor improved both IIEF scores and lower urinary tract symptom (LUTS) scores simultaneously [16]. Tadalafil 5 mg is FDA-approved for both ED and BPH/LUTS. This dual indication makes it a particularly efficient choice for men already on finasteride for prostate indications, though sildenafil remains effective for the erectile component alone.

When to Avoid the Combination

There is no absolute contraindication to prescribing sildenafil and finasteride together. Situations that require caution are the same as those for sildenafil monotherapy:

Concomitant nitrate therapy (nitroglycerin, isosorbide mononitrate/dinitrate) is an absolute contraindication for sildenafil regardless of whether finasteride is on board [2]. Concurrent alpha-blocker use requires sildenafil dose reduction to 25 mg, with the two drugs separated by at least four hours [2]. Severe hepatic impairment (Child-Pugh C) warrants a starting sildenafil dose of 25 mg, as clearance is reduced by approximately 47% [2].

Finasteride is contraindicated in women of childbearing potential due to teratogenicity risk (FDA Pregnancy Category X), but this does not affect the male patient taking both drugs [1].

The prescribing information for Viagra recommends a baseline cardiac evaluation for men with cardiovascular risk factors before initiating therapy, per the Princeton III Consensus guidelines, which stratify patients into low, intermediate, and high cardiac risk categories [17].